ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling

Jason E. Davis, Xiayang Xie, Jianhui Guo, Wei Huang, Wen Ming Chu, Shuang Huang, Yong Teng, Guangyu Wu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

ADP-ribosylation factor 1 (ARF1) is a crucial regulator in vesicle-mediated membrane trafficking and involved in the activation of signaling molecules. However, virtually nothing is known about its function in prostate cancer. Here we have demonstrated that ARF1 expression is significantly elevated in prostate cancer cells and human tissues and that the expression levels of ARF1 correlate with the activation of mitogen-activated protein kinases (MAPK) ERK1/2. Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059. Moreover, inhibition of ARF1 activation achieved by mutating Thr48 abolishes ARF1's abilities to activate the ERK1/2 and to promote cell proliferation. These data demonstrate that the aberrant MAPK signaling in prostate cancer is, at least in part, under the control of ARF1 and that, similar to Ras, ARF1 is a critical regulator in prostate cancer progression. These data also suggest that ARF1 may represent a key molecular target for prostate cancer therapeutics and diagnosis.

Original languageEnglish (US)
Pages (from-to)39834-39845
Number of pages12
JournalOncotarget
Volume7
Issue number26
DOIs
StatePublished - Jan 1 2016

Fingerprint

ADP-Ribosylation Factor 1
Mitogen-Activated Protein Kinases
Prostate
Carcinogenesis
Prostatic Neoplasms
Cell Proliferation
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase Kinases
Growth
Heterografts

Keywords

  • ARF1
  • Cell growth
  • Prostate cancer
  • Raf1/MEK/ERK1/2
  • Tumorigenesis

ASJC Scopus subject areas

  • Oncology

Cite this

Davis, J. E., Xie, X., Guo, J., Huang, W., Chu, W. M., Huang, S., ... Wu, G. (2016). ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. Oncotarget, 7(26), 39834-39845. https://doi.org/10.18632/oncotarget.9405

ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. / Davis, Jason E.; Xie, Xiayang; Guo, Jianhui; Huang, Wei; Chu, Wen Ming; Huang, Shuang; Teng, Yong; Wu, Guangyu.

In: Oncotarget, Vol. 7, No. 26, 01.01.2016, p. 39834-39845.

Research output: Contribution to journalArticle

Davis, JE, Xie, X, Guo, J, Huang, W, Chu, WM, Huang, S, Teng, Y & Wu, G 2016, 'ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling', Oncotarget, vol. 7, no. 26, pp. 39834-39845. https://doi.org/10.18632/oncotarget.9405
Davis JE, Xie X, Guo J, Huang W, Chu WM, Huang S et al. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. Oncotarget. 2016 Jan 1;7(26):39834-39845. https://doi.org/10.18632/oncotarget.9405
Davis, Jason E. ; Xie, Xiayang ; Guo, Jianhui ; Huang, Wei ; Chu, Wen Ming ; Huang, Shuang ; Teng, Yong ; Wu, Guangyu. / ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 39834-39845.
@article{95ba844dd47d4663a63557764e71ee13,
title = "ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling",
abstract = "ADP-ribosylation factor 1 (ARF1) is a crucial regulator in vesicle-mediated membrane trafficking and involved in the activation of signaling molecules. However, virtually nothing is known about its function in prostate cancer. Here we have demonstrated that ARF1 expression is significantly elevated in prostate cancer cells and human tissues and that the expression levels of ARF1 correlate with the activation of mitogen-activated protein kinases (MAPK) ERK1/2. Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059. Moreover, inhibition of ARF1 activation achieved by mutating Thr48 abolishes ARF1's abilities to activate the ERK1/2 and to promote cell proliferation. These data demonstrate that the aberrant MAPK signaling in prostate cancer is, at least in part, under the control of ARF1 and that, similar to Ras, ARF1 is a critical regulator in prostate cancer progression. These data also suggest that ARF1 may represent a key molecular target for prostate cancer therapeutics and diagnosis.",
keywords = "ARF1, Cell growth, Prostate cancer, Raf1/MEK/ERK1/2, Tumorigenesis",
author = "Davis, {Jason E.} and Xiayang Xie and Jianhui Guo and Wei Huang and Chu, {Wen Ming} and Shuang Huang and Yong Teng and Guangyu Wu",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9405",
language = "English (US)",
volume = "7",
pages = "39834--39845",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling

AU - Davis, Jason E.

AU - Xie, Xiayang

AU - Guo, Jianhui

AU - Huang, Wei

AU - Chu, Wen Ming

AU - Huang, Shuang

AU - Teng, Yong

AU - Wu, Guangyu

PY - 2016/1/1

Y1 - 2016/1/1

N2 - ADP-ribosylation factor 1 (ARF1) is a crucial regulator in vesicle-mediated membrane trafficking and involved in the activation of signaling molecules. However, virtually nothing is known about its function in prostate cancer. Here we have demonstrated that ARF1 expression is significantly elevated in prostate cancer cells and human tissues and that the expression levels of ARF1 correlate with the activation of mitogen-activated protein kinases (MAPK) ERK1/2. Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059. Moreover, inhibition of ARF1 activation achieved by mutating Thr48 abolishes ARF1's abilities to activate the ERK1/2 and to promote cell proliferation. These data demonstrate that the aberrant MAPK signaling in prostate cancer is, at least in part, under the control of ARF1 and that, similar to Ras, ARF1 is a critical regulator in prostate cancer progression. These data also suggest that ARF1 may represent a key molecular target for prostate cancer therapeutics and diagnosis.

AB - ADP-ribosylation factor 1 (ARF1) is a crucial regulator in vesicle-mediated membrane trafficking and involved in the activation of signaling molecules. However, virtually nothing is known about its function in prostate cancer. Here we have demonstrated that ARF1 expression is significantly elevated in prostate cancer cells and human tissues and that the expression levels of ARF1 correlate with the activation of mitogen-activated protein kinases (MAPK) ERK1/2. Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059. Moreover, inhibition of ARF1 activation achieved by mutating Thr48 abolishes ARF1's abilities to activate the ERK1/2 and to promote cell proliferation. These data demonstrate that the aberrant MAPK signaling in prostate cancer is, at least in part, under the control of ARF1 and that, similar to Ras, ARF1 is a critical regulator in prostate cancer progression. These data also suggest that ARF1 may represent a key molecular target for prostate cancer therapeutics and diagnosis.

KW - ARF1

KW - Cell growth

KW - Prostate cancer

KW - Raf1/MEK/ERK1/2

KW - Tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=84982947663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982947663&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9405

DO - 10.18632/oncotarget.9405

M3 - Article

VL - 7

SP - 39834

EP - 39845

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -